Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
| Status: | Terminated |
|---|---|
| Conditions: | Peripheral Vascular Disease, Neurology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | September 2014 |
| End Date: | July 2015 |
Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage
The investigators will test the central hypothesis that DFO treatment after SAH may improve
cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective
neuroprotectant against delayed ischemic injury after SAH.
cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective
neuroprotectant against delayed ischemic injury after SAH.
Inclusion Criteria:
- diagnosis of spontaneous SAH
- impaired cerebral autoregulation on day 2-4 post SAH
Exclusion Criteria:
- traumatic SAH
- other central neurological disorders such as tumors, known prior stroke, hemorrhage
or vascular malformations
- pregnancy
- severe renal disease or anuria
We found this trial at
1
site
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
